Press Releases

RARITAN, N.J., Nov. 8, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to expand the IMBRUVICA® (ibrutinib) label to include the combination with rituximab for the first-line tr

VANCOUVER, Nov. 8, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported

HAMPTON, N.H., Nov. 8, 2019 /PRNewswire/ -- Planet Fitness, Inc. (NYSE: PLNT), one of the largest and fastest-growing franchisors and operators of fitness centers in the U.S., today announced the Company's international expansion to Australia. The country's first official Judgement Free Zones® are located in Tuggerah and Gosford

NORTH CHICAGO, Ill., Nov. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IMBRUVICA® (ibrutinib) in combination with rituximab for the first-line treatment of younger patients (7

BERGEN, Norway, Nov. 8, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today presents comprehensive clinical and translational data from Cohort A of its Phase II clinical trial (BGBC008) evaluating bemcentinib, its first in class selective A

UPPSALA, Sweden , Nov. 8, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will present at the Jefferies Healthcare Conference on Wednesday, November 20, 2019, at 10.40 am GMT at the

SHENZHEN, China, Nov. 8, 2019 /PRNewswire/ -- The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, Sweden, Denmark, France,

PALO ALTO, Calif., Nov. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will report third quarter 2019 results on Tuesday, November 12, 2019.  Following the release of

BERKELEY, Calif., Nov. 8, 2019 /PRNewswire/ -- Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting data at the SITC Annual Meeting in National Harbor, Maryland on November 9, 2019. 

CAMBRIDGE, Mass., Nov. 8, 2019 /PRNewswire/ -- Boston Biomedical, Inc. today announced the presentation of new data from a phase 1 study evaluating DSP-7888, an investigational WT1 cancer peptide vaccine, in patients with advanced malignancies. Findings from the phase 1 study investigating the safety, tolerability, and determination of the recommended phase 2 dose of DSP